{"id":"levomilnacipran-hydrochloride-extended-release-capsules","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Nausea"},{"rate":"15-25","effect":"Headache"},{"rate":"10-20","effect":"Dizziness"},{"rate":"10-15","effect":"Insomnia"},{"rate":"10-15","effect":"Hyperhidrosis (excessive sweating)"},{"rate":"10-15","effect":"Constipation"},{"rate":"5-10","effect":"Tachycardia"},{"rate":"5-10","effect":"Increased blood pressure"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By inhibiting the reuptake of both serotonin and norepinephrine, levomilnacipran increases the availability of these neurotransmitters in the synaptic cleft, enhancing their signaling. The extended-release formulation provides sustained drug levels over 24 hours, allowing for once-daily dosing. This mechanism is thought to restore neurotransmitter balance in depression and other mood disorders.","oneSentence":"Levomilnacipran is a serotonin-norepinephrine reuptake inhibitor (SNRI) that increases levels of serotonin and norepinephrine in the brain by blocking their reuptake at the neuronal synapse.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:18:53.162Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"}]},"trialDetails":[{"nctId":"NCT07253207","phase":"PHASE3","title":"Efficacy and Safety Study of Levomilnacipran Hydrochloride Extended-Release Capsules in Major Depressive Disorder","status":"COMPLETED","sponsor":"Zhejiang Huahai Pharmaceutical Co., Ltd.","startDate":"2024-10-17","conditions":"Major Depressive Disorder (MDD)","enrollment":392}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Levomilnacipran Hydrochloride Extended-Release Capsules","genericName":"Levomilnacipran Hydrochloride Extended-Release Capsules","companyName":"Zhejiang Huahai Pharmaceutical Co., Ltd.","companyId":"zhejiang-huahai-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Levomilnacipran is a serotonin-norepinephrine reuptake inhibitor (SNRI) that increases levels of serotonin and norepinephrine in the brain by blocking their reuptake at the neuronal synapse. Used for Major depressive disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}